List of Excipients in Branded Drug OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN

« Back to Dashboard

Generic Drugs Containing OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN

Company	Ingredient	NDC	Excipient
Nostrum Laboratories Inc	oxycodone hydrochloride and acetaminophen	29033-405	ANHYDROUS CITRIC ACID
Nostrum Laboratories Inc	oxycodone hydrochloride and acetaminophen	29033-405	EDETATE DISODIUM
Nostrum Laboratories Inc	oxycodone hydrochloride and acetaminophen	29033-405	FD&C RED NO. 40

What are the Most Frequently-Used Excipients in OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN?

# Of NDCs	Excipient
2	ANHYDROUS CITRIC ACID
5	CELLULOSE, MICROCRYSTALLINE
1	COLLOIDAL SILICON DIOXIDE

Oxycodone Hydrochloride and Acetaminophen Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 5, 2026

Oxycodone hydrochloride/acetaminophen is a mature, immediate-release opioid combination with extensive generic competition and limited composition-of-matter protection. Commercial opportunity is concentrated in formulation differentiation, manufacturing efficiency, abuse-deterrence technology, patient-use improvements, and channel-specific products rather than in conventional generic tablets alone.

The key development constraints are opioid regulatory controls, acetaminophen exposure limits, abuse potential, controlled-substance distribution requirements, and the need to demonstrate bioequivalence against the selected reference product. The strongest commercial concepts are likely to combine low-cost excipients with measurable improvements in manufacturability, dose uniformity, stability, swallowability, taste, or tamper resistance.

What is the FDA regulatory status of oxycodone hydrochloride and acetaminophen?

Oxycodone hydrochloride/acetaminophen is an FDA-approved immediate-release prescription opioid combination. Oxycodone is a Schedule II controlled substance in the United States. Acetaminophen is a non-opioid analgesic and antipyretic.

The combination is marketed in several strengths, commonly expressed as oxycodone hydrochloride/acetaminophen:

Common strength	Oxycodone content	Acetaminophen content	Typical dosage form
2.5/325 mg	2.5 mg	325 mg	Immediate-release tablet
5/325 mg	5 mg	325 mg	Immediate-release tablet
7.5/325 mg	7.5 mg	325 mg	Immediate-release tablet
10/325 mg	10 mg	325 mg	Immediate-release tablet
5/300 mg and other variants	5 mg	300 mg	Tablet or capsule, depending on product

The commercial reference product historically associated with the combination is Percocet. FDA approval records and the Orange Book should be reviewed product-by-product because approval holders, discontinued status, listed patents, and reference-product designations can change over time.[1]

The FDA has approved multiple abbreviated new drug applications for oxycodone hydrochloride and acetaminophen tablets. Generic products generally rely on the 505(j) abbreviated pathway and must establish pharmaceutical equivalence and bioequivalence to the applicable reference-listed drug.[2]

What excipients are used in oxycodone hydrochloride and acetaminophen tablets?

Immediate-release tablets typically require excipients for binding, disintegration, lubrication, glidancy, coating, color, and stability. Exact compositions vary by manufacturer and may be disclosed in FDA labeling, DailyMed listings, ANDA product information, or patent filings.

Common excipient classes include:

Function	Representative excipient classes	Development objective
Diluent	Microcrystalline cellulose, lactose, dibasic calcium phosphate, mannitol	Tablet mass, compressibility, dose uniformity
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Rapid tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection and tooling protection
Glidant	Colloidal silicon dioxide, talc	Powder flow and content uniformity
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Identification, handling, light protection
Taste modifier	Sweeteners, flavors, ion-exchange resins, polymer coatings	Oral-liquid and orally disintegrating products
Preservative	Methylparaben, propylparaben, sodium benzoate, depending on product	Microbial control in liquid products
pH modifier	Citric acid, sodium citrate, phosphate buffers	Chemical stability and palatability

The two active ingredients present different formulation risks. Oxycodone hydrochloride is potent, so low-dose content uniformity is a central manufacturing issue. Acetaminophen represents the bulk of the tablet mass and can affect compactability, dissolution, and impurity formation. The formulation must prevent segregation between the low-dose opioid and the higher-load analgesic.

Which excipient strategies offer the strongest commercial opportunity?

Direct-compression formulation

A direct-compression platform can reduce processing steps, solvent use, drying time, and equipment requirements. The main technical challenge is achieving uniform distribution of oxycodone at low loading while retaining suitable hardness and rapid dissolution.

A viable platform may use:

• Co-processed microcrystalline cellulose and mannitol.
• A high-functionality binder with controlled particle size.
• Low-level colloidal silicon dioxide for flow.
• Sodium stearyl fumarate where magnesium stearate over-lubrication slows dissolution.
• A robust blending sequence validated for low-dose oxycodone distribution.

The commercial value is greatest for manufacturers seeking lower cost of goods and high-throughput production. A direct-compression patent would need to claim a non-obvious combination of excipient ratios, particle attributes, process parameters, or performance results. Generic formulation patents based only on routine excipient substitution face substantial obviousness risk.

Low-dose content-uniformity platform

The 2.5 mg oxycodone strength creates a larger content-uniformity challenge than higher-strength products. A drug-layering or pre-blend approach can improve distribution before final blending.

Potential strategies include:

1. Preparing an oxycodone-containing ordered mixture.
2. Applying oxycodone hydrochloride to a porous carrier.
3. Using granulation to immobilize the active on a carrier matrix.
4. Controlling particle-size distribution to minimize segregation.
5. Validating blend uniformity across commercial batch sizes.

A defensible patent position is more likely when the process produces a measurable improvement, such as tighter dosage-unit uniformity, reduced segregation, or lower sampling variability.

Fast-disintegrating tablets

Fast-disintegrating tablets can target patients with swallowing difficulty and selected outpatient settings. Crospovidone, croscarmellose sodium, or porous mannitol systems can support rapid dispersion.

The primary risks are opioid abuse, accidental exposure, friability, and the possibility that a rapidly disintegrating product increases misuse potential. Any orally disintegrating product would require careful control of taste, dose handling, packaging, and abuse-risk communication.

Oral solution and taste-masked liquid

An oxycodone/acetaminophen oral solution can address pediatric, geriatric, hospice, and post-surgical patients who cannot swallow tablets. The product is technically more complex because it must control:

• Chemical stability of both active ingredients.
• Oxycodone solubility and pH dependence.
• Acetaminophen precipitation risk.
• Preservative effectiveness.
• Microbial quality.
• Taste and mouthfeel.
• Dosing-device accuracy.
• Accidental ingestion risk.

Taste masking is commercially important but difficult because oxycodone is bitter and opioid products require strict packaging and distribution controls. A taste-masked suspension may offer differentiation, but sedimentation, resuspendability, dose uniformity, and abuse concerns create higher development costs than a tablet.

Tamper-resistant and abuse-deterrent excipients

The FDA’s abuse-deterrent guidance describes evaluation of physical and chemical barriers, agonist-antagonist approaches, aversion, delivery-system controls, and combinations of technologies.[3] A new oxycodone/acetaminophen product could pursue abuse-deterrent labeling only if it satisfies FDA expectations through appropriate laboratory, pharmacokinetic, and potentially clinical studies.

Potential excipient systems include:

• High-viscosity polymers that resist crushing and solvent extraction.
• Gelling matrices that limit syringeability.
• Thermoplastic or wax-like barriers.
• Ion-exchange systems.
• Sequestered or aversive components.
• Coatings designed to resist mechanical manipulation.

A conventional immediate-release tablet should not be marketed as abuse-deterrent merely because it is hard or difficult to crush. FDA labeling depends on demonstrated properties and an approved product-specific claim.[3]

The economic opportunity is potentially meaningful in institutional, payer, and public-sector channels. Development risk is also substantially higher than for a standard ANDA, and the product may require a 505(b)(2) strategy rather than a conventional 505(j) approach if the formulation materially differs from the reference product.

What patents protect oxycodone hydrochloride and acetaminophen products?

The original oxycodone and acetaminophen combination patents are expired or commercially ineffective against ordinary generic entry. The current patent opportunity is generally limited to later-arising product, formulation, manufacturing, packaging, or abuse-deterrence claims.

Relevant patent categories include:

Patent category	Commercial relevance	Orange Book potential
Active-ingredient composition	Minimal for mature actives	Usually expired
Tablet formulation	Can protect a specific product composition	Potentially listable if tied to approved product
Modified-release formulation	High value but outside ordinary immediate-release substitution	Potentially listable
Abuse-deterrent formulation	Potentially high value	Potentially listable
Oral liquid or suspension	Niche opportunity	May be listable if product-specific
Manufacturing process	Can reduce copying but often not Orange Book listable	Generally not listable as a process patent
Method of treatment	Can protect labeled use	May be listable, subject to FDA rules
Packaging or dosing device	Commercial differentiation	Listing depends on patent and product relationship
Salt, particle size, or solid form	Limited value for an established hydrochloride product	Depends on approved-product linkage

The Orange Book does not create a broad monopoly over the active ingredients. It records certain patents submitted by NDA holders for approved drug products and methods of use. A generic applicant may challenge listed patents through Paragraph IV certification or use a section viii statement to carve out a patented method of use.[1,4]

For a new product, the strongest Orange Book strategy would usually involve claims directed to the approved drug product itself, such as a defined excipient matrix, abuse-deterrent structure, or drug-release profile. Purely manufacturing-oriented claims may remain enforceable but typically do not provide the same ANDA-based litigation leverage.

When does oxycodone hydrochloride and acetaminophen lose exclusivity?

The combination has already lost conventional market exclusivity for standard immediate-release tablets. Generic entry is established, and multiple manufacturers compete across common strengths.

The relevant exclusivity framework is:

Protection	Status for mature immediate-release combination
New chemical entity exclusivity	Not available for a long-established combination
Five-year NCE exclusivity	Expired or unavailable
Three-year clinical-investigation exclusivity	Relevant only to qualifying later approvals
Orphan exclusivity	Not applicable to ordinary analgesic use
Pediatric exclusivity	Product-specific and time-limited
Patent exclusivity	Primarily expired foundational protection; later formulation patents may differ
Controlled-substance regulation	Continues after patent expiry and affects distribution

A new abuse-deterrent or otherwise differentiated product could obtain limited regulatory exclusivity if it qualifies under the applicable statutory pathway, but that protection would attach to the specific approval and supporting clinical investigations rather than restore exclusivity to the entire oxycodone/acetaminophen market.

How many patents cover oxycodone hydrochloride and acetaminophen?

There is no meaningful single patent count for the entire product category. Patent coverage depends on:

• The selected reference-listed drug.
• The strength and dosage form.
• The applicant’s formulation.
• The regulatory pathway.
• The jurisdiction.
• Whether the patent is active, expired, abandoned, or listed.
• Whether claims cover the product, method of use, or manufacturing process.

For standard immediate-release generic tablets, the practical patent barrier is low. A company developing a differentiated formulation may create a new patent estate around:

1. Excipient composition.
2. Particle engineering.
3. Abuse-deterrent performance.
4. Oral-liquid stability.
5. Taste masking.
6. Dose-uniformity manufacturing.
7. Unit-dose packaging.
8. Dosing-device integration.

Patent strength will depend on claim breadth, reproducibility, freedom-to-operate analysis, and the ability to demonstrate that the formulation produces a technical effect not predicted by routine formulation practice.

What Paragraph IV challenges and litigation risks exist?

Paragraph IV risk is most relevant when a manufacturer files an ANDA that references a product with unexpired listed patents. For a conventional immediate-release oxycodone/acetaminophen generic, the principal litigation risk is usually lower than for a recently approved controlled-release opioid or an abuse-deterrent product.

Potential litigation issues include:

• Whether a formulation claim covers the ANDA product.
• Whether the patent is valid over earlier opioid and acetaminophen formulations.
• Whether the asserted claims are enabled across the full scope.
• Whether the generic product induces infringement of a patented method.
• Whether the applicant can use a section viii carveout.
• Whether the patent was properly listed in the Orange Book.
• Whether the product label creates a direct infringement theory.

Historical opioid litigation has been extensive, but national opioid settlements and public nuisance proceedings generally do not determine patent validity or generic approval rights. Product-specific ANDA litigation must be analyzed through FDA records and federal court dockets.

A settlement can delay launch, permit an authorized generic, grant a license, or establish a negotiated entry date. Any settlement involving a branded or differentiated oxycodone product should also be assessed under the Federal Trade Commission’s pharmaceutical settlement review framework.[5]

How does oxycodone hydrochloride and acetaminophen compare with competing opioid products?

Product category	Patent barrier	Excipient opportunity	Commercial outlook
Oxycodone/acetaminophen immediate-release tablet	Low for ordinary generic products	Cost, uniformity, tablet robustness, packaging	High-volume but price competitive
Oxycodone extended-release	Higher for selected branded formulations	Release control and abuse deterrence	Greater regulatory and litigation complexity
Hydrocodone/acetaminophen	Mature generic market	Similar tablet and liquid opportunities	Direct therapeutic competitor
Tramadol/acetaminophen	Mature market, different pharmacology	Oral dosage and tolerability improvements	Less intense controlled-substance profile in some markets
Oxycodone oral solution	Product-specific barriers	Taste masking, stability, dosing device	Niche institutional and home-care opportunity
Abuse-deterrent opioid	Potentially stronger formulation estate	Polymer, coating, extraction resistance	Higher development cost and differentiated pricing potential

The primary commercial advantage of oxycodone/acetaminophen is established prescribing familiarity. The principal disadvantage is commoditization and regulatory scrutiny surrounding opioid distribution.

What manufacturing and intellectual-property barriers affect commercialization?

Manufacturing barriers are more important than active-ingredient access. Oxycodone hydrochloride is commercially available only through controlled-substance channels, and manufacturers must comply with DEA registration, quota controls, security requirements, recordkeeping, and suspicious-order monitoring.[6]

Key manufacturing risks include:

• Low-dose oxycodone segregation.
• Cross-contamination control.
• Batch reconciliation and controlled-substance accountability.
• Tablet weight variation.
• Acetaminophen impurity management.
• Dissolution variability caused by lubricant overuse.
• Stability under heat and humidity.
• Packaging that limits diversion and accidental exposure.
• Supply continuity for qualified excipients.

A formulation patent should be paired with process know-how. Excipients that are technically effective but difficult to source at commercial scale may weaken the product’s economic value. Co-processed excipients can simplify development but may introduce supplier dependence and new qualification requirements.

What geographic opportunities exist for oxycodone hydrochloride and acetaminophen?

The United States is the most structured market for Orange Book, ANDA, Paragraph IV, DEA, and opioid REMS analysis. Canada, Europe, Australia, and selected Latin American markets have different controlled-substance rules, labeling systems, reimbursement structures, and opioid utilization patterns.

A global excipient platform should account for:

• Different maximum acetaminophen labeling conventions.
• Country-specific opioid scheduling.
• Local bioequivalence requirements.
• Variations in permitted colorants and preservatives.
• Pharmacopoeial standards.
• Packaging and child-resistant requirements.
• National reimbursement and tender systems.

The most transferable technology is generally a manufacturing platform or excipient system that improves tablet robustness, uniformity, stability, or taste without relying on a U.S.-specific regulatory claim.

What is the commercial opportunity for a new oxycodone hydrochloride and acetaminophen product?

The market divides into four practical opportunities:

1. Low-cost ANDA tablet: Fastest path, lowest differentiation, and highest price pressure.
2. Institutional-strength product: Unit-dose packaging, barcode integration, tamper-evident presentation, and inventory controls.
3. Patient-use formulation: Smaller tablets, orally disintegrating dosage forms, or liquids for swallowing-limited populations.
4. Abuse-deterrent product: Higher investment, stronger potential differentiation, and greater FDA evidence requirements.

Revenue exposure is linked to opioid prescription volume, payer substitution, wholesaler access, DEA supply limits, and state-level opioid controls. A standard generic tablet is unlikely to command durable premium pricing. A product that reduces administration errors, improves dose uniformity, or solves a defined care-setting problem has a stronger commercial case.

Key Takeaways

• Oxycodone hydrochloride/acetaminophen is a mature generic combination with limited foundational patent protection.
• Excipient strategy should prioritize content uniformity, direct compression, dissolution control, stability, taste masking, and abuse-deterrent performance.
• Standard immediate-release tablets face intense price competition.
• Oral liquids, low-dose strengths, institutional packaging, and abuse-deterrent formulations offer the clearest differentiation.
• Orange Book value is strongest for patents claiming the approved product itself, not merely a manufacturing process.
• Paragraph IV risk is generally limited for ordinary generic tablets but can increase substantially for differentiated or abuse-deterrent products.
• DEA controls, opioid REMS obligations, supply quotas, and diversion controls are central commercial constraints.
• The strongest patent estate would combine formulation claims, process know-how, validated technical effects, and product-specific regulatory positioning.

FAQs About Oxycodone Hydrochloride and Acetaminophen Excipient Strategy

Can a new excipient combination receive patent protection?

Yes. Protection is possible when the combination produces a patentable formulation or manufacturing result, such as improved content uniformity, stability, abuse resistance, or dissolution. Routine substitution of one conventional excipient for another is more vulnerable to obviousness challenges.

Is an oxycodone and acetaminophen oral liquid commercially attractive?

It can address patients who cannot swallow tablets, but it requires stronger controls for taste, microbial quality, dosing accuracy, chemical stability, and accidental ingestion. The opportunity is more specialized than the tablet market.

Can an abuse-deterrent oxycodone product use the 505(j) pathway?

Possibly, but the pathway depends on the degree of formulation similarity to the reference product and the nature of the proposed labeling. A materially different abuse-deterrent formulation may require a 505(b)(2) application.

Are manufacturing patents listed in the Orange Book?

Usually not. Orange Book listing generally focuses on patents that claim the approved drug substance, drug product, or an approved method of use. Process patents may remain enforceable without creating the same ANDA certification framework.

Does acetaminophen content create a formulation patent opportunity?

It can. Potential areas include impurity control, chemical stabilization, modified particle engineering, dissolution balancing, and reduced tablet burden. The patent must establish a defensible technical result rather than simply claim a conventional strength.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA): Generics. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

3. U.S. Food and Drug Administration. (2015). General principles for evaluating abuse deterrence of generic solid oral opioid drug products: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-evaluating-abuse-deterrence-generic-solid-oral-opioid-drug-products

4. U.S. Food and Drug Administration. (2024). Approved drug product and therapeutic equivalence evaluations. DailyMed and Orange Book regulatory materials.

5. Federal Trade Commission. (2024). Agreement filings under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. https://www.ftc.gov

6. U.S. Drug Enforcement Administration. (2024). Controlled substance schedules and pharmaceutical controlled-substance requirements. https://www.deadiversion.usdoj.gov